497 related articles for article (PubMed ID: 30273068)
1. Secukinumab efficacy in the treatment of nail psoriasis: a case series.
Pistone G; Gurreri R; Tilotta G; Castelli E; Bongiorno MR
J Dermatolog Treat; 2018; 29(sup1):21-24. PubMed ID: 30273068
[TBL] [Abstract][Full Text] [Related]
2. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
[TBL] [Abstract][Full Text] [Related]
3. Rapid response of nail psoriasis to secukinumab in patients with moderate to severe psoriasis after 12 weeks of treatment with a total of 24 weeks of follow-up.
Go GM; Hong YJ; Lee HJ; Kim M
Australas J Dermatol; 2024 May; 65(3):e13-e20. PubMed ID: 38288519
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
5. Approach to managing patients with nail psoriasis.
Reich K
J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
Rigopoulos D; Gregoriou S; Makris M; Ioannides D
Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab provides sustained improvement in nail psoriasis, signs and symptoms of psoriatic arthritis and low rate of radiographic progression in patients with concomitant nail involvement: 2-year results from the Phase III FUTURE 5 study.
Nash P; Mease PJ; Kirkham B; Singhal A; Quebe-Fehling E; Pricop L; Gaillez C
Clin Exp Rheumatol; 2022 May; 40(5):952-959. PubMed ID: 34494957
[TBL] [Abstract][Full Text] [Related]
9. Treatment of nail psoriasis with adalimumab: an open label unblinded study.
Rigopoulos D; Gregoriou S; Lazaridou E; Belyayeva E; Apalla Z; Makris M; Katsambas A; Ioannides D
J Eur Acad Dermatol Venereol; 2010 May; 24(5):530-4. PubMed ID: 19807825
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial.
Elewski BE; Okun MM; Papp K; Baker CS; Crowley JJ; Guillet G; Sundaram M; Poulin Y; Gu Y; Geng Z; Williams DA; Rich PA
J Am Acad Dermatol; 2018 Jan; 78(1):90-99.e1. PubMed ID: 28993005
[TBL] [Abstract][Full Text] [Related]
11. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
Luger TA; Barker J; Lambert J; Yang S; Robertson D; Foehl J; Molta CT; Boggs R
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
[TBL] [Abstract][Full Text] [Related]
13. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy).
Sánchez-Regaña M; Sola-Ortigosa J; Alsina-Gibert M; Vidal-Fernández M; Umbert-Millet P
J Eur Acad Dermatol Venereol; 2011 May; 25(5):579-86. PubMed ID: 21198950
[TBL] [Abstract][Full Text] [Related]
14. Comparison of NAPSI and N-NAIL for evaluation of fingernail psoriasis in patients with moderate-to-severe plaque psoriasis treated using ustekinumab.
Kim BR; Yang S; Choi CW; Youn SW
J Dermatolog Treat; 2019 Mar; 30(2):123-128. PubMed ID: 29757042
[TBL] [Abstract][Full Text] [Related]
15. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
Jemec GB; Ibler KS
J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one-blind, randomized study.
Gümüşel M; Özdemir M; Mevlitoğlu I; Bodur S
J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1080-4. PubMed ID: 21118309
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.
Reich K; Sullivan J; Arenberger P; Jazayeri S; Mrowietz U; Augustin M; Elewski B; You R; Regnault P; Frueh JA
Br J Dermatol; 2021 Mar; 184(3):425-436. PubMed ID: 32479641
[TBL] [Abstract][Full Text] [Related]
18. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
[TBL] [Abstract][Full Text] [Related]
19. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
[TBL] [Abstract][Full Text] [Related]
20. Nail Involvements as an Indicator of Skin Lesion Severity in Psoriatic Patients.
Darjani A; Nafezi R; Moladoust H; Eftekhari H; Nejad KG; Rafiei R; Alizadeh N; Azimi SZ
Acta Dermatovenerol Croat; 2018 Dec; 26(4):307-313. PubMed ID: 30665480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
